Support for Patients and Communities Reauthorization Act
This bill reauthorizes through FY2028 and modifies various grants, programs, and activities that address substance use and misuse.
This includes reauthorizing (1) data collection, education, and surveillance activities; (2) grants and other support for substance use disorder prevention, treatment, and recovery; (3) student loan repayment and other programs for the substance use disorder workforce; and (4) programs for addressing trauma, particularly for children, youth, and their families. Generally, the modifications expand programs.
Additionally, the bill modifies provisions related to the scheduling of controlled substances, including by incorporating illicit xylazine (a compound used in veterinary medicine as a nonopioid tranquilizer) into schedule III of the Controlled Substances Act.
Further, the bill makes permanent a requirement that Medicaid programs cover medication-assisted treatment for individuals with substance use disorders.
The Support for Patients and Communities Reauthorization Act, also known as Bill 118 hr 4531, is a piece of legislation currently being considered by the US Congress. This bill aims to address the ongoing opioid crisis in the United States by providing support and resources for patients and communities affected by opioid addiction.
The main provisions of the bill include increasing funding for opioid treatment and prevention programs, expanding access to medication-assisted treatment for individuals struggling with opioid addiction, and improving coordination between federal, state, and local agencies in addressing the crisis. Additionally, the bill seeks to enhance data collection and reporting on opioid-related deaths and overdoses to better understand the scope of the problem and inform future policy decisions.
Overall, the Support for Patients and Communities Reauthorization Act is a comprehensive effort to combat the opioid crisis and provide much-needed support for individuals and communities impacted by addiction. It represents a bipartisan effort to address a pressing public health issue and has the potential to make a significant impact in the fight against opioid abuse in the United States.
Alternative Names
Official Title as IntroducedTo reauthorize certain programs that provide for opioid use disorder prevention, recovery, and treatment, and for other purposes.
Display TitleSupport for Patients and Communities Reauthorization Act
Short Title(s) as Passed HouseSupport for Patients and Communities Reauthorization Act
Short Title(s) as IntroducedSupport for Patients and Communities Reauthorization Act
Official Title as IntroducedTo reauthorize certain programs that provide for opioid use disorder prevention, recovery, and treatment, and for other purposes.
Policy Areas
Health
Potential Impact
Administrative law and regulatory procedures•
Cardiovascular and respiratory health•
Child safety and welfare•
Computers and information technology•
Congressional oversight•
Department of Health and Human Services•
Digestive and metabolic diseases•
Drug safety, medical device, and laboratory regulation•
Drug trafficking and controlled substances•
Drug, alcohol, tobacco use•
Employment and training programs•
Family services•
First responders and emergency personnel•
Government information and archives•
Government studies and investigations•
HIV/AIDS•
Health care coverage and access•
Health information and medical records•
Health personnel•
Health promotion and preventive care•
Labor market•
Medicaid•
Mental health•
Prescription drugs•
Smuggling and trafficking•
State and local finance•
State and local government operations•
Student aid and college costs•
Transportation costs•
Unemployment•
Veterinary medicine and animal diseases•
Women's health
Comments
Most relevant
Recent Activity
Latest Summary12/18/2023
Support for Patients and Communities Reauthorization Act
This bill reauthorizes through FY2028 and modifies various grants, programs, and activities that address substance use and misuse.
This includes reauthorizing (1) data ...
collection, education, and surveillance activities; (2) grants and other support for substance use disorder prevention, treatment, and recovery; (3) student loan repayment and other programs for the substance use disorder workforce; and (4) programs for addressing trauma, particularly for children, youth, and their families. Generally, the modifications expand programs.
Additionally, the bill modifies provisions related to the scheduling of controlled substances, including by incorporating illicit xylazine (a compound used in veterinary medicine as a nonopioid tranquilizer) into schedule III of the Controlled Substances Act.
Further, the bill makes permanent a requirement that Medicaid programs cover medication-assisted treatment for individuals with substance use disorders.
Latest Action12/13/2023
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.